This collaboration is in addition to Biocon Biologics’ own insulin aspart drug product for the US, which is currently under ...

Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in ...

Cite this: What's Next? Clinical Trials in Myelofibrosis - Medscape - Mar 06, 2025.